The U.S. Patent and Trademark Office (USPTO) has granted Conduit Pharmaceuticals a patent for AZD1656, its experimental therapy for…
Articles by Marisa Wexler, MS
Disease symptoms among people with ANCA-associated vasculitis (AAV) were found to vary by age at diagnosis and biological sex,…
The likelihood of disease recurrence in people with anti-neutrophilic cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) varies by disease type, with those…
Lixudebart (ALE.F02), an experimental therapy Alentis Therapeutics is developing to help preserve kidney health in ANCA-associated vasculitis (AAV),…
Self-reactive antibodies, or autoantibodies, against two proteins — homeostatic iron regulator, or HFE, and synaptotagmin 5, known as SYT5 —…
ADX-097, an experimental tissue-targeted therapy that Q32 Bio is developing for ANCA-associated vasculitis (AAV) and other diseases marked…
Blood tests that look for the anti-neutrophil cytoplasmic autoantibodies (ANCAs) that cause ANCA-associated vasculitis (AAV) may help identify…
The production of new B-cells, a type of immune cell that helps fight infections but is also involved in the…
Symptoms and disease manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), a rare type of ANCA-associated vasculitis (AAV), are generally…
Rituximab is superior to other immunosuppressive treatments at preventing post-surgery relapse in granulomatosis with polyangiitis (GPA) patients undergoing…